DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT02255266

Completed

Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in Daily Practice

Lead sponsor

Novo Nordisk A/S

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

1,788

actual

Study population

Type 2 diabetes

Key I/E criterion

—

Primary endpoint

•HbA1c, change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02255266
Org study IDNN2211-4118
Secondary IDU1111-1143-9842WHO

Timeline

Milestones

Study first posted2014-10-02estimated
Study start2015-03-26actual
Primary completion2015-11-16actual
Study completion2015-11-16actual
Last update posted2018-04-17actual

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Type 2 diabetes

Eligibility

Who can enroll

SexAll
Healthy volunteersNot accepted
Sampling methodNon probability sample

Study population text

All consecutive subjects initiating liraglutide in 2011 according to Victoza® SmPC meeting the inclusion criteria will be enrolled.

Inclusion criteria

•Subjects of age above 18 years as per Victoza® SmPC par.4.2 and 5.1 diagnosed with type 2 diabetes receiving the first prescription of liraglutide in 2011

Exclusion criteria

•None. Available data from all eligible patients for each center, will be included

Endpoints (9)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Glycemic / diabetes
4
Weight & body composition
2
Cardiometabolic biomarkers
1
Safety / tolerability / PK
1
Other (unclassified)
1

Weight & body composition

2 endpoints
Secondary/protocol endpoint

Change in body weight

Time frame:Week 0, week 104

Body weight, absolute change (kg)

change from baseline, improvement

Secondary/protocol endpoint

Frequency of patients achieving a body weight reduction of at least 3%

Time frame:After 4, 12 and 24 months

threshold achievement, improvement

Glycemic / diabetes

4 endpoints
Primary/protocol endpoint

Frequency of patients achieving HbA1c reduction of at least 1%-point

Time frame:Week 0, week 52

HbA1c, change

threshold achievement, improvement

LOINC 4548-4

Secondary/protocol endpoint

Change in HbA1c (Glycosylated haemoglobin))

Time frame:Week 0, week 104

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Secondary/protocol endpoint

Frequency of patients achieving HbA1c reduction of at least 1%-point

Time frame:After 4 and 24 months of treatment

threshold achievement, improvement

LOINC 4548-4

Secondary/protocol endpoint

Frequency of patients achieving HbA1c target (<=7%)

Time frame:After 4, 12 and 24 months

HbA1c <7.0% achievement

threshold achievement, improvement

LOINC 4548-4

Cardiometabolic biomarkers

1 endpoint
Secondary/protocol endpoint

Changes in blood pressure and lipid profile

Time frame:Week 0, week 104

change from baseline, improvement

Safety / tolerability / PK

1 endpoint
Secondary/protocol endpoint

Percentage of treatment discontinuation for any reason

Time frame:At 4, 12 and 24 months

Discontinuation due to AE

event count, event

Other (unclassified)

1 endpoint
Secondary/protocol endpoint/low confidence

Frequency of patients achieving the composite endpoint consisting in: HbA1c reduction of at least 1%-point and body weight reduction of at least 3%

Time frame:After 4, 12 and 24 months

threshold achievement, improvement

componentsHbA1c, change, Body weight, % change

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.